Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.
Getting focused has been the catchphrase of the pharma industry for a couple of years, and its reach includes contract manufacturers no less than the Big Pharma players. French CMO Novasep said today that its "back to basics" strategy, which included some changes in its manufacturing network, has paid off with improved financials.
The $335 million Merck & Co. biologics plant in Ireland that went online last year is already getting another investment. Merck said last week that it would invest €11.5 million ($12.4 million) in the Carlow facility.
GlaxoSmithKline is recalling 1.7 million doses of its quadrivalent flu vaccine that were manufactured at a plant that ran into a series of manufacturing issues last year including an FDA warning letter. The company says there are questions about whether the vaccine is retaining its potency.
Contract manufacturer Norwich Pharma Services, which last year said it would be laying off about a fourth of its workforce, will now invest about $26 million in new equipment at its facility in Norwich, NY.
Sanofi's highly anticipated dengue vaccine is being manufactured in a facility in France built specifically for the product. But expansion is also going on at Sanofi Pasteur's vaccine operation in Swiftwater, PA, in preparation for a launch of the vax which may happen later this year.
CDMO Catalent started nearly two years ago on an expansion that it said would cost about $35 million and add about 80,000 square feet to its operation in Winchester, KY. But with additional investments in fluid bed capacity, the project ended up running to $52 million for an expansion of about 90,000 square feet, nearly double its original footprint.
Bayer said it will boost its already big footprint in the Bay Area with a $100 million investment in its Berkeley, CA, facility that is focused on developing new treatments for hemophilia.
The GlaxoSmithKline plant in Dungarvan, Ireland, is making measurable headway in reducing its carbon footprint and appears to be on track to reach its goal of nipping two-thirds of its emissions over the next two years.
U.K. respiratory drug specialist Vectura picked up a plant last year when it bought Germany's Activaero in a €130 million ($181 million) deal. But Vectura has decided it doesn't need it and will close the facility within a year in a cost-saving move.